Mandate

Vinge advises Embracer in connection with the financing of its intended acquisition of Asmodee

December 16, 2021 Banking and Finance

Embracer Group AB (publ) has entered into exclusive negotiations to acquire the Asmodee group from amongst others funds advised or managed by PAI Partners SAS. The acquisition is subject to completion of the consultation of the relevant works council and exercise by the shareholders of Asmodee of their sell option.

Vinge has advised Embracer in connection with the signing of a new SEK 18 billion facilities agreement with SEB, Nordea and Swedbank for the purpose of, amongst other things, financing the acquisition.

Embracer Group is the parent company of businesses developing and publishing PC, console and mobile games for the global games market. With its head office based in Karlstad, Sweden, Embracer Group has a global presence through eight operative groups with 86 internal game development studios, and is engaging more than 9,000 employees and contracted employees in more than 40 countries.

Vinges consisted of Louise Brorsson Salomon, Lionardo Ojeda and Felix Möller.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026